Log in

BidaskClub Downgrades Celldex Therapeutics (NASDAQ:CLDX) to Hold

Last updated on Wednesday, July 15th, 2020 by MarketBeat

Celldex Therapeutics (NASDAQ:CLDX) was downgraded by stock analysts at BidaskClub from a "buy" rating to a "hold" rating in a report released on Wednesday, BidAskClub reports.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Celldex Therapeutics from a "sell" rating to a "hold" rating and set a $14.00 price objective on the stock in a report on Monday, July 6th. Cantor Fitzgerald raised their price objective on shares of Celldex Therapeutics from $12.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, July 1st. ValuEngine lowered shares of Celldex Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Finally, HC Wainwright restated a "buy" rating and set a $16.00 target price (down from $19.00) on shares of Celldex Therapeutics in a research report on Friday, March 27th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of "Hold" and an average target price of $16.00.

CLDX stock opened at $10.36 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.03. Celldex Therapeutics has a twelve month low of $1.50 and a twelve month high of $13.91. The company's 50 day moving average is $8.16 and its two-hundred day moving average is $3.73. The stock has a market cap of $251.77 million, a P/E ratio of -3.50 and a beta of 3.46.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.02). Celldex Therapeutics had a negative return on equity of 47.60% and a negative net margin of 948.81%. The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $1.28 million. On average, equities research analysts predict that Celldex Therapeutics will post -2.41 earnings per share for the current year.

In other Celldex Therapeutics news, CFO Samuel Bates Martin bought 9,750 shares of the stock in a transaction dated Tuesday, June 9th. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $29,152.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Anthony S. Marucci bought 15,000 shares of the stock in a transaction dated Tuesday, June 9th. The shares were acquired at an average price of $2.99 per share, for a total transaction of $44,850.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 41,170 shares of company stock worth $126,778. Insiders own 2.40% of the company's stock.

A number of large investors have recently bought and sold shares of CLDX. Acadian Asset Management LLC grew its position in Celldex Therapeutics by 20.4% in the 1st quarter. Acadian Asset Management LLC now owns 298,649 shares of the biopharmaceutical company's stock valued at $496,000 after buying an additional 50,583 shares during the last quarter. TSP Capital Management Group LLC grew its position in Celldex Therapeutics by 14.9% in the 1st quarter. TSP Capital Management Group LLC now owns 410,017 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 53,127 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Celldex Therapeutics by 8.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,115,368 shares of the biopharmaceutical company's stock valued at $2,487,000 after buying an additional 89,083 shares during the last quarter. Hedge funds and other institutional investors own 17.61% of the company's stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Recommended Story: Accumulation/Distribution

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Rock-Solid Dividend Paying Stocks to Own

Historically low interest rates have made it difficult over the last decade for income-oriented investors that want to generate safe cash flow for their retirements.

Dividend-paying stocks have become more appealing to income investors because of their competitive yields, the favorite tax treatment that dividends receive and their ability to grow their payouts over time. While fixed interest rates from bond investments will lose purchasing power to inflation over time, the purchasing power of income from dividend growth stocks is more protected because companies tend raise their dividend payments every year.

In this slideshow, we look at ten of the best high-dividend stocks that offer strong yields (above 3.5%), have consistent cashflow and a strong track record of dividend growth. The companies in this slideshow have all raised their dividend every year for the last ten years.

These companies also have low payout ratios (below 75%), meaning that they will have the ability to continue to pay their dividend if their earnings have a temporary dip.

Stock prices will always fluctuate, but the dividends paid by these rock-solid dividend payers should remain secure with moderate earnings growth.

View the "10 Rock-Solid Dividend Paying Stocks to Own".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.